{"id":605,"date":"2025-01-27T23:35:23","date_gmt":"2025-01-27T23:35:23","guid":{"rendered":"https:\/\/perfusfind.com\/ic\/?p=605"},"modified":"2025-01-27T23:35:23","modified_gmt":"2025-01-27T23:35:23","slug":"host-response-biomarkers-for-sepsis-in-the-emergency-room","status":"publish","type":"post","link":"https:\/\/perfusfind.com\/ic\/index.php\/2025\/01\/27\/host-response-biomarkers-for-sepsis-in-the-emergency-room\/","title":{"rendered":"Host Response Biomarkers for Sepsis in the Emergency Room"},"content":{"rendered":"

Abstract<\/strong><\/p>\n

This review explores the role of host response biomarkers in diagnosing, prognosticating, and managing sepsis in the emergency room (ER). It highlights the benefits of traditional biomarkers like procalcitonin (PCT) and C-reactive protein (CRP) and emerging tools from transcriptomics, proteomics, and metabolomics to improve patient outcomes and advance precision medicine in sepsis care.<\/p>\n

Key Points<\/strong><\/p><\/blockquote>\n

    \n
  1. Traditional Biomarkers<\/strong>: Procalcitonin (PCT) and C-reactive protein (CRP) are widely used biomarkers, with PCT providing faster and more specific diagnostic utility compared to the broader but less specific CRP.<\/li>\n
  2. Emerging Biomarkers<\/strong>: Presepsin, a biomarker under investigation, has shown higher diagnostic and prognostic accuracy than CRP in several studies but requires further evaluation against PCT.<\/li>\n
  3. Proadrenomedullin<\/strong>: Proadrenomedullin (MR-proADM) is a promising marker of endothelial dysfunction, correlating strongly with sepsis severity and providing additional prognostic insights over traditional biomarkers.<\/li>\n
  4. Transcriptomics<\/strong>: Advances in transcriptomics enable identification of sepsis endotypes through gene classifiers, facilitating precision medicine approaches by linking patient-specific immune responses to tailored therapies.<\/li>\n
  5. Proteomics and Metabolomics<\/strong>: These emerging fields help uncover metabolic and protein signatures of sepsis, enhancing our understanding of disease mechanisms and improving diagnostic accuracy through advanced technologies like mass spectrometry.<\/li>\n
  6. Theragnostics<\/strong>: Biomarkers such as suPAR provide predictive insights into patient response to targeted therapies, including interventions involving IL-6 and IL-1 pathway modulation.<\/li>\n
  7. Diagnostic Panels<\/strong>: Combining multiple biomarkers into diagnostic panels has improved accuracy, particularly for distinguishing bacterial from viral infections and identifying high-risk sepsis patients.<\/li>\n
  8. Point-of-Care Testing<\/strong>: The development of point-of-care testing platforms for biomarker panels promises to streamline sepsis management in ER settings, reducing diagnostic delays and enabling timely interventions.<\/li>\n
  9. Barriers to Adoption<\/strong>: Challenges such as variability in biomarker performance, lack of validation across diverse populations, and high costs hinder the widespread clinical integration of these tools.<\/li>\n
  10. Future Directions<\/strong>: Further research is needed to validate biomarker panels and omics-based tools in larger, diverse patient cohorts, as well as to explore cost-effective solutions for their integration into clinical practice.<\/li>\n<\/ol>\n

    ACCESS FULL ARTICLE HERE<\/strong><\/a><\/p>\n

    Open Access<\/b>\u00a0This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit\u00a0http:\/\/creativecommons.org\/licenses\/by\/4.0\/<\/a>. The Creative Commons Public Domain Dedication waiver (http:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/<\/a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.<\/p>\n